Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277376 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial
A Phase 3 study, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
NCT05277376 is a Phase 3 study that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 162 participants.
The verdict
NCT05277376, a Phase 3 study, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
Study Summary
An open-label, randomized, 3-arm study in 162 healthy adult subjects with the following primary objective: To assess the systemic absorption and pharmacokinetics of BEMT from 3 market image sunscreen formulations under maximal-use conditions.
Interventions
- DRUG Bemotrizinol (6%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05277376
The ClinicalTrials.gov registry entry for NCT05277376 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is dsm-firmenich Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bemotrizinol (6%) is the first listed.
NCT05277376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05277376 about?
NCT05277376 is a clinical study titled "Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial". An open-label, randomized, 3-arm study in 162 healthy adult subjects with the following primary objective: To assess the systemic absorption and pharmacokinetics of BEMT from 3 market image sunscreen formulations under maximal-use conditions.
What is the current status of trial NCT05277376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2022-03-15. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05277376?
The interventions under investigation include: Bemotrizinol (6%) (DRUG).
Who is sponsoring clinical trial NCT05277376?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.